FayeM.JohnsonMDPhD

PubMed

• Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.
  Faye M Johnson, Madison P O'Hara, Lacin Yapindi, Peixin Jiang, Hai T Tran
  Clinical Cancer Research. 2024-11-26
• Revisiting Feeding Tube Utilization in Oropharynx Cancer: 6-Year Prospective Registry Analysis.
  Brady J Anderson, Amy C Moreno, Yun Qing, J Jack Lee, Faye M Johnson
  Otolaryngology--Head and Neck Surgery. 2024-05-01
• 2 citations
  Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas.
  Amanda-Louise Fenger Carlander, Simone Kloch Bendtsen, Jacob H Rasmussen, Kathrine Kronberg Jakobsen, Martin Garset-Zamani
  European Journal of Cancer. 2024-05-01

Journal Articles

• Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients with Incurable Human Papillomavirus 16–Related Cancer  
  Erminia Massarelli, William William, Ming Guo, Merrill Kies, Bonnie Glisson, Hai Tran, Faye Johnson, Renata Ferrarotto, Lei Feng, JAMA
• Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies Across Platinum-Resistant Cancers  
  Faye M Johnson, John V Heymach, Lauren Averett Byers, Clinical Cancer Research
• CDKN2A/p16 deletion in head and neck cancer cells is associated with Cdk2 activation, replication stress, and vulnerability to Chk1 inhibition  
  Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwoo..., Cancer Res, 1/1/2018
• Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer  
  Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne..., Invest New Drugs, 1/1/2018
• Essential role of DNA methyltransferase 1-mediated transcription of insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors  
  Min HY, Lee SC, Woo JK, Jung HJ, Park KH, Jeong HM, Hyun SY, Cho J, Lee W, Park JE, Kwon SJ, Lee HJ, Ni X, Shin YK, Johnson FM, Duvic M, Lee HY, Clin Cancer Res, 1/1/2017
• Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer  
  Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch..., JCI Insight, 1/1/2017
• Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors  
  Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM, Cancer Lett, 1/1/2017
• Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy  
  Quinlan-Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, Skinner H, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morris..., Oral Oncol, 1/1/2017
• Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer  
  Ferrarotto R, Goonatilake R, Young Yoo S, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J,..., Clin Cancer Res, 1/1/2016
• Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer  
  Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J, J Clin Oncol, 1/1/2016
• Gene mutations in primary tumors and corresponding patient derived xenografts derived from non-small cell lung cancer  
  Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, ..., Cancer Lett, 1/1/2015
• Wee-1 kinase inhibition sensitizes high risk HPV+ HNSCC to apoptosis accompanied by down regulation of MCl-1 and XIAP antiapoptotic proteins  
  Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA, Clin Cancer Res, 1/1/2015
• Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers  
  Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM, Journal of Translational Medicine, 1/1/2013
• Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin Beta3-Src Pathway  
  Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY, J Natl Cancer Inst, 1/1/2013
• Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancer  
  Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ, J Clin Oncol, 1/1/2010
• Strategies in the Chemoprevention of Lung Cancer  
  Kim ES, Johnson F, Hong WK, Khuri FR, Chemoprevention, 1/1/2003
• Join now to see all

Books/Book Chapters

• In Serpins and Protein Kinase Inhibitors 
  Chapter: Src Family Kinase Inhibitors in Cancer Therapy 
  Johnson FM and Gallick GEEditors: Georgiev B, Markovski S.Nova Science Publishers, Inc.2009
• MD Anderson Manual of Clinical Oncology 
  Chapter: Non-small Cell Lung Cancer 
  Johnson FM and Pisters KMEditors: Kantarjian HN, Koller CM, Wolff R.McGraw Hill, New York, NY2006
• Cancer Chemoprevention 
  Chapter: Strategies in the Chemoprevention of Lung Cancer 
  Kim ES, Johnson FM, Hong WK, Khuri FREditors: Koller G, Hawk ET, Sigman CC.Human Press, Totowa, NJ2004

Abstracts/Posters

• PI3K/mTOR pathway inhibition induces Aurora B mediated cell death in NOTCH1 mutant head and neck squamous (HNSCC) cells.
  Sambandam V, Shen L, Tong P, Mazumdar T, Singh R, Pickering CR, Myers JN, Wang J, Frederick M, Johnson FM, American Association for Cancer Research Annual Meeting (AACR), Chicago, IL, 1/1/2018
• Pharmacogenomic screen identifies KMT2D mutations as a biomarker of sensitivity to Aurora kinase inhibition in head and neck and cervical squamous cell carcinoma.
  Mazumdar T, Kalu NN, Peng S, Tong P, Shen Li, Wang J, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM, American Association for Cancer Research Annual Meeting (AACR), Chicago, IL, 1/1/2018
• Noncanonical c-Met activation mediates de novo and acquired resistance to polo-like kinase 1 inhibitor-induced apoptosis in non-small cell lung cancer.
  Singh S, Viswanath P, Peng S, Sambandam V, Shen L, Li L, Wang J, Fang B, Johnson FM, American Association for Cancer Research Annual Meeting (AACR), Chicago, IL, 1/1/2018
• Metabolic dysregulation drives sensitivity after PI3K/mTOR inhibition in HNSCC.
  Sambandam V, Shen L, Ton P, Mazumdar T, Jong J, Pickering C, Myers JN, Wang J, Frederick M, Johnson FM, J Cancer Sci Ther, 1/1/2017
• Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or met...
  William WN, Feng L, Kies MS, Ahmed S, Blumenschein GR, Glisson BS, Massarelli E, Johnson FM, Lu C, Papadimitrakopoulou V, Gold KA, Theriault RL, Heymach J, Kim ES, American Society of Clinical Oncology (ASCO) Annual Meeting, 1/1/2017
• Mutations of the lim protein ajuba mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell cycle inhibitors.
  Zhang M, Ratnakar S, Peng S, Mazumdar T, Li S, Tong P, Pickering C, Myers JN, Wang J, Johnson FM., American Association for Cancer Research Annual Meeting (AACR), Washington, DC, 1/1/2017
• Identification of NOTCH1 inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC).
  Sambandam V, Shen L, Tong P, Mazumdar T, Pickering C, Myers JN, Wang J, Frederick M, Johnson FM, American Association for Cancer Research Annual Meeting (AACR), Washington, DC, 1/1/2017
• Gay CM, Tong P, Cardnell RJ, Su Xiao, Kalu NN, Banerjee U, Bara RO, Johnson FM, Heymach JV, Wang J, Byers LA, American Association for Cancer Research Annual Meeting (AACR), Washington, DC, 1/1/2017
• c-Met activation mediates resistance to polo-like kinase 1 inhibitor-induced apoptosis in non-small cell lung cancer.
  Singh R, Shen L, Tong P, Wang J, Johnson FM, American Association for Cancer Research Annual Meeting (AACR), Washington, DC, 1/1/2017
• Identification of biomarkers that predict response of head and neck squamous cell carcinoma to mitotic inhibitors.
  Zhang M, Peng S, Mazumdar T, Sambandam V, Li S, Tong P, Li L, Byers L, Pickering C, Frederick M, Myers JN, Wang J, Johnson FM, American Association of Cancer Research (AACR), New Orleans, LA, 1/1/2016
• The combination of Polo-Like Kinase 1 inhibition and erlotinib overcomes T790M-mediated drug resistance in vitro and in vivo in non-small cell lung cancer.
  Singh R, Wang Y, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Wang J, Heymach JV, Johnson FM, American Association of Cancer Research (AACR), New Orleans, LA, 1/1/2016
• NOTCH1 inactivating mutation mediates sensitivity to PI3K/mTOR inhibitors in Head and Neck Squamous Cell Carcinoma.
  Sambandam V, Shen L, Ming Z, Saigal R, Tong P, Mazumdar T, Byers LA, Frederick M, Pickering C, Myers JN, Wang J, Johnson FM, American Association of Cancer Research (AACR), New Orleans, LA, 1/1/2016
• Cell-based, high throughput screen for small molecule inducers of cell death in HPV-associated head and neck cancers.
  Kalu NN, Mazumdar T, Shen L, Tong P, Wang J, Byers LA, Johnson FM, American Association of Cancer Research (AACR), New Orleans, LA, 1/1/2016
• Identifying Biomarkers of Response to NMS-P937, a Novel PLK1 Inhibitor in NSCLC.
  Singh R, Giri U, Peng S, Heymach J, Tong P, Wang J, Johnson FM, TxSACT Conference: Recent Advances in the Development of Combinatorial Therapies for Cancer, 1/1/2015
• Synergistic Effect of Polo-Like Kinase 1 and Epidermal Growth Factor Receptor (EGFR) Inhibition in Non-Small Cell Lung Cancer Cell Lines with Acquired EGFR Inhibitor R...
  Wang Y, Nilsson, M, Heymach J, Goonatilake R, Giri U, Peng S, Tong P, Wang J, Johnson FM, TxSACT Conference: Recent Advances in the Development of Combinatorial Therapies for Cancer, 1/1/2015
• Integrating "Multiple-Omics" Data with Targeted Drug Screen of PI3K/mTOR Pathway Inhibitors to Identify Novel Combination Therapies for Head and Neck Squamous Cell Car...
  Sambandam V, Shen L, Zhang M, Saigal R, Tong P, Mazumdar T, Byers LA, Pickering C, Myers JN, Wang J, Johnson FM, TxSACT Conference: Recent Advances in the Development of Combinatorial Therapies for Cancer, 1/1/2015
• Identification of Mitotic Inhibitors as Effective Drugs in HNSCC and Potential of Biomarkers of Response.
  Zhang M, Mazumdar T, Sambandam V, Peng S, Tong P, Shen L, Myers J, Wang J, Johnson FM, TxSACT Conference: Recent Advances in the Development of Combinatorial Therapies for Cancer, 1/1/2015
• Determining the Mechanism of Antagonism between PLK1 Inhibitors and DNA-Damaging Agents.
  Wang L, Singh R, Giri U, Peng S, Heymach J, Tong P, Shen L, Zhang M, Wang J, Johnson FM, TxSACT Conference: Recent Advances in the Development of Combinatorial Therapies for Cancer, 1/1/2015
• Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer.
  Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Wheler J, Zinner RG, Janku F, Fu S, Dandu L, Browne E, Meric-Bernstam F, Ho..., American Society of Clinical Oncology - Illumination & Innovation, 1/1/2015
• The difference of drug sensitivity between HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines.
  Zhang M, Mazumdar T, Peng S, Tong P, Sambandam V, Byers L, Myers J, Wang J, Johnson FM, American Association for Cancer Research Annual Meeting, Philadelphia, PA, 1/1/2015
• Integrative drug sensitivity analysis of PI3K /mTOR pathway inhibitors in Head and Neck Squamous cell carcinoma (HNSCC).
  Sambandam V, Shen L, Ming Z, Saigal R, Byers LA, Pickering C, Myers JN, Wang J, Johnson FM, American Association for Cancer Research (AACR) Annual Meeting, 1/1/2015
• Characterization of HPV-positive head and neck cancer cell lines as preclinical models for targeted therapy.
  Kalu N, Mazumdar T, Fan YH, Giri U, Diao L, Ng PKS, Wang J, Myers J, Johnson FM, Byers LA, American Association for Cancer Research, Philadelphia, PA, 1/1/2015
• Postoperative IMRT for Patients with Oral Cavity Carcinoma.
  Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, Johnson FM, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William Jr WN, Fuller CD, Gold KA, Rosenthal DI, Garden AS, ASTRO 56th Annual Meeting - Targeting Cancer:Technology & Biology, 1/1/2014
• Kinase-impaired BRAF mutations as predictors of resistance and sensitivity.
  Johnson F, Sen, Banibrata, Muzumdar T, Peng S, Kadara H, Diao L, Byers L, AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy, 1/1/2014
• Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated p...
  Massarelli E, Haddad RI, Lee JJ, Garden AS, Blumenschein Jr GR, William WN, Tishler, RB, Glisson BS, Gold KA, Johnson FM, Ginsberg LE, Williams MD, Myers J, Kies MS, P..., American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2014
• Join now to see all

Lectures

• Redefining Perceptions in Locally Advanced Disease 
  Chicago, IL - 1/1/2018
• Puerto Rico Cancer Conferences Series 2017: Head and Neck Cancer Management 
  Ponce School of Medicine & Health Sciences, PR - 1/1/2017
• "Frontiers in Cancer Research and Therapy" - Targeting polo-like kinase 1 in mesenchymal non-small cell lung cancer 
  Karolinska Institutet, Dept. of Oncology, Stockholm, Sweden - 1/1/2017
• Advanced Topics in Cancer: Emerging Technologies for Detection and Treatment of Cancer 
  University of Puerto Rico Comprehensive Cancer Center, San Juan, PR - 1/1/2017
• Prevention and Treatment of Cancer: Hypes and Hopes 
  Ahmedabad, India - 1/1/2016
• Mechanisms of Apoptosis Following Polo-like Kinase Inhibition in Head and Neck Squamous Cell Carcinoma 
  MD Anderson Cancer Center, Cancer Medicine, Houston, TX - 1/21/2015
• Recent Advances in the Development of Combinatorial Therapies for Cancer 
  Institute of Biosciences and Technology - Texas A&M Health Science Center - 1/1/2015
• Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer 
  Texas A&M University, Houston, TX - 1/1/2015
• Drug Sensitivity and Resistance: Improving Cancer Therapy 
  Orlando, FL - 1/18/2014
• Advances in the Understanding of Lung Cancer Biology: Translation to Clinical Practice 
  University of Puerto Rico, PR - 1/1/2014
• BEZ235 Targeted Therapy for Lung Cancer 
  San Monica, CA - 1/1/2013
• Novel Signaling Pathways as Therapeutic Targets in Lung and Head & Neck Cancers 
  Zhejiang Cancer Hospital, Hangzhou, China - 1/1/2013
• Novel Signaling Pathways as Therapeutic Targets in Lung and Head and Neck Cancer 
  Miami, FL - 1/1/2013
• Dasatinib, Targeted Therapies for the Treatment of lung cancer 
  San Monica, CA - 1/1/2012
• Advances in Lung Cancer Biology 
  San Juan, PR - 1/1/2011
• Targeted Therapy for Lung Cancer 
  China - 1/1/2011
• A novel feedback pathway leading to STAT3 activation following c-SRC inhibition 
  MD Anderson Cancer Center, Cancer Medicine, Houston, TX - 1/24/2010
• JAK Activation as a Mechanism for Resistance to c-Src Inhibition in NSCLC 
  Coronado, CA - 1/1/2010
• Small Cell Lung Cancer 
  Baylor College of Medicine, Hematology and Oncology, Houston, TX - 1/1/2010
• The Role of JAK Activation Following Sustained c-Src Inhibition 
  The University of Michigan Cancer Center Seminar, Ann Arbor, MI - 1/1/2009
• The Src Inhibitor KX2-391 Targeted Therapies for the Treatment of lung Cancer 
  San Monica, CA - 1/1/2009
• Sustained c-Src Inhibition Results in JAK/STAT3 Activation Allowing Cancer Cell Survival in Lung and Head and Neck Cancers 
  University of Colorado Cancer Center, Denver, CO - 1/1/2009
• Molecular and Biological Effects of Src Family Kinase Inhibition in Head and Neck Cancer 
  San Diego, CA - 1/1/2008
• Src Family Kinases as Therapeutic Targets in Lung Cancer 
  Santa Monica, CA - 1/1/2008
• Src Family Kinases as Therapeutic Targets in Cancer 
  Tampa, FL - 1/1/2008
• Join now to see all

Other

• c-Src Family of Tyrosine Kinases. 
  Sen B, Johnson FM, Encyclopedia of Signaling Molecules Part 4
  1/1/2011